Friday, March 29, 2024
ADVT 
International

Moderna says its vaccine can protect those affected by sever COVID19 cases 100 percent

Darpan News Desk Darpan, 01 Dec, 2020 12:00 AM
  • Moderna says its vaccine can protect those affected by sever COVID19 cases 100 percent

A major breakthrough from the pharmaceutical company Moderna today promising a coronavirus vaccine that is 100 percent effective against severe Covid-19 and there appears to be no evidence that efficacy is worse at older ages. These are primary results of the study. Englnad has secured seven million doses of enough for around 3.5 million people in the UK.

Moderna said the analysis of the phase three COVE study of the vaccine candidate, called mRNA-1273, involving 30,000 participants included 196 cases of Covid-19, of which 30 cases were severe. Vaccine efficacy against the disease was 94.1 per cent, and vaccine efficacy against severe Covid-19 was 100 per cent. 

It added that the jab is generally well tolerated with no serious safety concerns identified to date. Announcing the results on Monday, Moderna said it has submitted emergency use authorisation from the US Food and Drug Administration (FDA), to apply for a conditional marketing authorisation with the European Medicines Agency (EMA) and to progress with the rolling reviews, which have already been initiated with international regulatory agencies.

Stephane Bancel, chief executive of Moderna, said: "This positive primary analysis confirms the ability of our vaccine to prevent Covid-19 disease with 94.1 per cent efficacy and importantly, the ability to prevent severe Covid-19 disease. "We believe that our vaccine will provide a new and powerful tool that may change the course of the pandemic and help prevent severe disease, hospitalisations and death."

The analysis released on Monday was based on 196 cases, of which 185 cases of Covid-19 were observed in the placebo group, versus 11 cases observed in the vaccinated group.

MORE International ARTICLES

FDA approves first COVID-19 drug: antiviral remdesivir

FDA approves first COVID-19 drug: antiviral remdesivir
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

FDA approves first COVID-19 drug: antiviral remdesivir

Here we go again: Trump, Biden reprise debate duel

Here we go again: Trump, Biden reprise debate duel
Instead, they're bracing for another show of vintage Trump, one in which he'll seek to be heard even in spite of his muted microphone.

Here we go again: Trump, Biden reprise debate duel

Getting ready for the gong show: Trump v. Biden II

Getting ready for the gong show: Trump v. Biden II
It's the sequel to last month's debate horror show between Donald Trump and Joe Biden, an invective-laced 90 minutes that laid bare the depths to which political discourse can sink in an American election year.

Getting ready for the gong show: Trump v. Biden II

US overdose deaths appear to rise amid coronavirus pandemic

US overdose deaths appear to rise amid coronavirus pandemic
Davidson lost his job. He started staying home alone in his apartment near Georgetown, Kentucky — depressed and yearning for his recovery support group that had stopped gathering in person, said his cousin Melanie Wyatt.

US overdose deaths appear to rise amid coronavirus pandemic

Pfizer: Mid-November earliest it can seek virus vaccine OK

Pfizer: Mid-November earliest it can seek virus vaccine OK
Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.

Pfizer: Mid-November earliest it can seek virus vaccine OK

UN: Europe's pandemic restrictions are absolutely necessary

UN: Europe's pandemic restrictions are absolutely necessary
In a meda briefing on Thursday, Dr. Hans Kluge warned that even more drastic steps might be needed in such “unprecedented times.”

UN: Europe's pandemic restrictions are absolutely necessary